Leqvio (inclisiran) is an oligonucleotide pharmaceutical. Inclisiran was first approved as Leqvio on 2020-12-09. It has been approved in Europe to treat dyslipidemias and hypercholesterolemia.
Trade Name |
Leqvio |
Common Name |
Inclisiran |
Indication |
dyslipidemias, hypercholesterolemia |
Drug Class |
|